ACAna Chopitea

Ana Chopitea

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Chopitea has a total of 240 co-authors. Here are the top co-authors by number of shared publications:

  • J. Rodriguez

    Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain

    15 shared publications
  • J. Garcia-Foncillas

    12 shared publications
  • Javier Rodriguez

    Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain

    11 shared publications
  • A. Viudez

    Clinica Universitaria de Navarra, Pamplona, Spain; University of Navarra, Pamplona, Spain; Clinica Universidad de Navarra, Pamplona, Spain

    10 shared publications
  • Javier Aristu

    Department of Radiation Oncology, Clinica Universidad de Navarra, 28027 Madrid, Spain

    9 shared publications
  • L. Arbea

    Department of Oncology, Unit for the Research and Treatment of Gastrointestinal Cancer, Clínica Universidad de Navarra, University of Navarra, Avenida Pío XII 36, 31008, Pamplona, Spain

    8 shared publications

Latest Publications

  • Open Access

    Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling

    by Patricia Martin-Romano, Belén P. Solans, David Cano, Jose Carlos Subtil, Ana Chopitea, Leire Arbea, Maria Dolores Lozano, Eduardo Castanon, Iosune Baraibar, Diego Salas, et al.

    Perioperative chemotherapy (CT) or neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced gastric (GC) or gastroesophageal junction cancer (GEJC) has been shown to improve survival compared to an exclusive surgical approach. However, most patients retain a poor prognosis due to important relapse rates. Population pharmacokinetic-pharmacodynamic (PK/PD) modeling may allow identifying at risk-patients. We aimed to develop a mechanistic PK/PD model to characterize the relationship between the type of neoadjuvant therapy, histopathologic response and survival times in locally advanced GC and GEJC patients. Patients with locally advanced GC and GEJC treated with neoadjuvant CT with or without preoperative CRT were analyzed. Clinical response was assessed by CT-scan and EUS. Pathologic response was defined as a reduction on pTNM stage compared to baseline cTNM. Metastasis development risk and overall survival (OS) were described using the population approach with NONMEM 7.3. Model evaluation was performed through predictive checks. A low correlation was observed between clinical and pathologic TNM stage for both T (R = 0.32) and N (R = 0.19) categories. A low correlation between clinical and pathologic response was noticed (R = -0.29). The OS model adequately described the observed survival rates. Disease recurrence, cTNM stage ≥3 and linitis plastica absence, were correlated to a higher risk of death. Our model adequately described clinical response profiles, though pathologic response could not be predicted. Although the risk of disease recurrence and survival were linked, the identification of alternative approaches aimed to tailor therapeutic strategies to the individual patient risk warrants further research.


  • Open Access

    A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis

    by Javier Rodriguez, Eduardo Castañón, Jose Luis Perez-Gracia, Inmaculada Rodriguez, Antonio Viudez, Carlos Alfaro, Carmen Oñate, Guiomar Perez, Fernando Rotellar, Susana Inogés, et al.

    Surgically resectable synchronic and metachronic liver metastases of colon cancer have high risk of relapse in spite of standard-of-care neoadjuvant and adjuvant chemotherapy regimens. Dendritic cell vaccines loaded with autologous tumor lysates were tested for their potential to avoid or delay disease relapses (NCT01348256). Patients with surgically amenable liver metastasis of colon adenocarcinoma (n = 19) were included and underwent neoadjuvant chemotherapy, surgery and adjuvant chemotherapy. Fifteen patients with disease-free resection margins were randomized 1:1 to receive two courses of four daily doses of dendritic cell intradermal vaccinations versus observation. The trial had been originally designed to include 56 patients but was curtailed due to budgetary restrictions. Follow-up of the patients indicates a clear tendency to fewer and later relapses in the vaccine arm (median disease free survival –DFS-) 25.26 months, 95% CI 8.74-n.r) versus observation arm (median DFS 9.53 months, 95% CI 5.32–18.88).


  • Segmental Pneumonitis after Radioembolization

    by José I. Bilbao Jaureguizar, Lidia Sancho, María Páramo, Macarena Rodríguez-Fraile, Ana Chopitea, Alberto Benito, Mercedes Iñarrairaegui, Bruno Sangro


  • Adjuvant Therapy for Colon Cancer: Genes, Genes… and the Patient in the Center

    by Javier Rodriguez, Silvestre Vicent, Ana Chopitea, Mariano Ponz-Sarvisé

    Although molecular subtype–based stratification and genomic signatures of increasing complexity are becoming a new strategy to guide therapeutic decisions in stage II/III colon cancer, several prognostic factors that can be easily obtained from formalin-fixed paraffin-embedded (FFPE) specimens should be considered to create combined models that better define individual patients' needs. Clin Cancer Res; 24(16); 3787–9. ©2018 AACR. See related article by Kandimalla et al., p. 3867


  • Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience

    by L. Ceniceros, A. Chopitea, F. Pardo, F. Rotellar, L. Arbea, J. J. Sola, J. C. Subtil, B. Sangro, A. Benito, J. L. Hernández-Lizoain, et al.

    Synchronous liver metastases (LM) from gastric (GC) or esophagogastric junction (EGJ) adenocarcinoma are a rare events. Several trials have evaluated the role of liver surgery in this setting, but the impact of preoperative therapy remains undetermined.


  • Open Access

    Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer

    by Patricia Martin-Romano, Jose J Sola, Juan A Diaz-Gonzalez, Ana Chopitea, Yohana Iragorri, Fernando Martínez-Regueira, Mariano Ponz-Sarvise, Leire Arbea, Jose C Subtil, David Cano, et al.

    The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.


  • Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery

    by J. Arredondo, J. Baixauli, C. Pastor, A. Chopitea, J. J. Sola, I. González, J. A-Cienfuegos, P. Martínez, J. Rodriguez, J. L. Hernández-Lizoain

    Neoadjuvant chemotherapy is being actively tested as an emerging alternative for the treatment of locally advanced colon cancer (LACC) patients, resembling its use in other gastrointestinal tumors. This study assesses the mid-term oncologic outcome of LACC patients treated with oxaliplatin and fluoropyrimidines-based preoperative chemotherapy followed by surgery. Patients with radiologically resectable LACC treated with neoadjuvant therapy between 2009 and 2014 were retrospectively analyzed. Radiological, metabolic, and pathological tumor response was assessed. Both postoperative complications, relapse-free survival (RFS), and overall survival (OS) were studied. Sixty-five LACC patients who received treatment were included. Planned treatment was completed by 93.8 % of patients. All patients underwent surgery without delay. The median time between the start of chemotherapy and surgery was 71 days (65–82). No progressive disease was observed during preoperative treatment. A statistically significant tumor volume reduction of 62.5 % was achieved by CT scan (39.8–79.8) (p < 0.001). It was also observed a median reduction of 40.5 % (24.2–63.7 %) (p < 0.005) of SUVmax (Standard Uptake Value) by PET-CT scan. Complete pathologic response was achieved in 4.6 % of patients. Postoperative complications were observed in 15.4 % of patients, with no cases of mortality. After a median follow-up of 40.1 months, (p25–p75: 27.3–57.8) 3–5 year actuarial RFS was 88.9–85.6 %, respectively. Five-year actuarial OS was 95.3 %. Preoperative chemotherapy in LACC patients is safe and able to induce major tumor regression. Survival times are encouraging, and further research seems warranted.


    • 1 June 2015
      • Vol. 107  (6) , 340-6

    Long-term oncologic results in cancer of the rectum treated by preoperative chemoradiotherapy and surgery: An analysis of 500 cases.

    by Javier A Cienfuegos, Jorge Baixauli, Carlos Pastor, Jorge Arredondo, Jesús Javier Sola, Leire Arbea, Ana Chopitea, José Luis Hernández-Lizoáin

    The standard treatment for locally advanced cancer of the rectum (LACR) and selective cases of stage IV disease is preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME). Despite reductions in local recurrence, disease-free survival (DSF) has remained stable in recent years. The objective of this study is to analyze patterns of recurrence, long-term survival and prognostic factors in a program of neoadjuvant CRT and surgery in LACR. Between January 1992 and December 2011, 446 patients with LACR and 54 patients (with single metastases) were treated with pre-operative long course CRT and surgery. Three hundred forty four (66.8%) anterior resections of the rectum and 123 (24.6%) abdomino-perineal resections were performed. With a mean follow-up of 70.06 months, local recurrence was 4.8% and distant recurrence 25.5%. No differences were found in the histopathologic prognostic factors across the three groups studied depending on distance (cm) from the analmargin. Involvement of the circumferential resection margin (CRM+) was significantly greater in tumors in the distal third of the rectum (8.5%; p = 0.04). 67 patients (13.4%) showed a complete pathologic response. DSF at 5 and 10 years was significantly lower in patients with tumors affecting the distal third as compared to the middle third of the rectum (61.9% vs. 57.7%; p = 0.04). Tumors at this distal location resulted in a significantly higher incidence of lung metastases (p = 0.016).


  • A pilot study of oxaliplatin, irinotecan and PK-adjusted 5-fluorouracil within a neoadjuvant multidisciplinary approach in locally advanced pancreatic cancer patients.

    by Patricia Martin Romano, Azucena Aldaz, Ana Chopitea, Fernando Pardo, Leire Arbea, Jose Carlos Subtil, Fernando Rotellar, Laura Zufia, Jose Luis Solorzano, Juan Pablo Fusco, et al.

    E15220 Background: The aim of this study was to evaluate the feasibility and efficacy of FOLFOXIRI induction chemotherapy (ICT) with pharmacokinetic (PK) dose adjustment of 5-FU followed by chemo-radiotherapy (CRT) and surgery (S) in Locally Advanced Pancreatic Cancer patients (pts) Methods: Borderline resectable and unresectableLAPC pts with EUS stages T3-4/N+ were included. ICT consisted of 4 cycles of Oxalipatin (85mg/m²), Leucovorin (400mg/m²), Irinotecan (150mg/m²) and 5-FU [initial dose of 3200mg/m² in 46h; subsequent doses based on PK-guided dose adjustments (therapeutic AUC of 20-30 mg∙h∙L-1)]. 5-FU concentrations were analyzed by High-performanced Liquid Chromatography. PK parameters were estimated by Bayesian Methodology with Multiple Dose Software. Pts with no progressive disease after ICT were planned to receive CRT. Surgery (S) was planned 4 to 6 weeks after completion of CRT. Toxicity was recorded according to the NCI-CTCAE 4.0 Results:From November 2011 to August 2014, 23 LAPC treatment-naï...